Trial Profile
First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Anfibatide (Primary)
- Indications Acute coronary syndromes; Embolism and thrombosis; Myocardial infarction; Unstable angina pectoris
- Focus Adverse reactions
- 24 Jul 2013 Results were presented at the XXIV Congress of the International Society on Thrombosis and Haemostasis (ISTH), according to a Lee's Pharmaceutical Holdings media release.
- 03 May 2012 New trial record